Keywords: osi, tarceva, earns, 0m, 4th-qtr, usa, pharmaceuticals
OSI's Tarceva earns $25.0M in 4th-qtr 2005
Article | 13 February 2006
The USA's OSI Pharmaceuticals says that international sales of its flagship product Tarceva (erlotinib) were $25.0 million for the fourth quarter ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
